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Abstract 
 
Indonesia global health insurance system was established since January, 1st 2014. 
This is an effort to all Indonesian for increasing highest degree of their health statue. 
One indicator of the effectiveness and efficiency of health services is to minimize length 
of stay. This is encourage multidisciplinary to implementing clinical pathway for some 
diagnose as quality control and cost control. 
This study conducted by analitycal survey with a retrospective design on SNH 
patients hospitalized at Panti Rapih Hospital from July to December 2014 that were used 
medical record of patients during care, data collecting techniques were used study 
documentation and interview. Total subjects were 68, consisted 34 before clinical 
pathway group and 34 after clinical pathway group.  
The averages of SNH patients on LOS both without other variable correlation and 
complication disease correlation before and after clinical pathway implementation were 
(P < 0,05) meanwhile average stroke non hemorrhagic patients on cost of treatment 
both group without other variable correlation and complication disease correlation 
before and after clinical pathway implementation were (P >0,05). 
There were any difference about LOS and cost of treatment because of clinical 
pathway on SNH patients with complication, however clinical pathway couldn’t changed 
SNH patients without complication.  
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A.  Introduction 
Integrated care pathways are structured 
multidisciplinary care plans which detail 
essensial steps in cares of patients with a specific 
clinical problem. They have been proposed as a 
way of encouraging the translation of national 
guidelines into local protocols and their 
subsequent application to clinical practice. They 
are also a mean of improving systematic 
collection and abstraction of clinical data for 
audit and promoting change in practice1. 
Ischemic stroke results in bland (non 
hemorrhagic) ischemia and infarction in a 
typically vascular distribution. The vascular 
distribution is often very helpful in 
differentiating stroke from tumor or demyelin2. 
Highly number of stroke non hemorrhagic 
patients at Panti Rapih Hospital approximately 
60 – 70 patients with their highly cost of 
treatment encouraging medical committee to 
implementing clinical pathway for stroke non 
hemorrhagic disease.  
Based on previous study in medical record 
instalation at Panti Rapih Hospital taken by 
January 12th – 15th, 2015. Clinical pathway were 
evaluated by CP’s team that has been 
implemented for some diagnose. There were 
Partus Spontan, Pre Eclampsia, Dengue Fever of 
Children, Non STEMI, STEMI, Stroke Non 
Hemorrhagic, BPH, and Fracture Femur. These 
diagnose have chosen because of highly 
increased of these disease sufferer and these cost 
of treatment. From sample that were taken on 
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earlier study, there were 40 medical records of 
stroke non hemorrhagic patients devided into 20 
medical records were before clinical pathway 
and 20 medical records were after clinical 
pathway. Stroke non hemorrhagic has chosen 
because it had the highest number of patients 
that hospitalized than others.  
 
B.  Method 
The study was conducted by analitycal 
survey with retrospective design on stroke non 
hemorrhagic patients hospitalized at Panti Rapih 
Hospital from July to December 2014 that were 
used medical records of patients during care, 
data collecting techniques used study 
documentation and interview. Total number of 
subjects were 68, consisted of 34 patients before 
clinical pathway and 34 patients after clinical 
pathway. Data were analyzed with statistic to 
evaluate the average of Length Of Stay (LOS) and 
Cost Of Treatment  with early examination data 
distribution. Because of both these variable   
hadn’t normally distributed so data were 
analyzed by Mann Whitney U Test. It is used 
because data was statistic non parametric, each 
variable hadn’t  correlation to another. The 
conclusion can be take by the results of Mann 
Whitney U test with the results of (sig) or p 
value. If p value < 0,05 means that there are 
significant difference and p value > 0,05 that 
means no significant difference. 
 
C.  Result and discussion 
Based on study documentation result, all 
medical records patient hospitalized during 2014 
period at Panti Rapih there were consisted of 
stroke, stroke ischemic, and stroke hemorrhagic 
with its code I64, I63.-, and I61.9 were 672. 
Afterwards, population of stroke non 
hemorrhagic only was chosen in July to 
December period. July to September without 
clinical pathway and October to December with 
clinical pathway. 
1. Data distribution of age 
The average of stroke non hemorrhagic 
patients before clinical pathway were 63,97 
± 8,744 with range of age 50 – 83 while 
after clinical pathway were 63,03  ± 11,642 
with range of age 38 – 87. The result of 
Mann Whitney U test explained that p value 
> 0,05 it was concluded that there was no 
significant difference about both of group. 
The same result was showed before, with 
data distribution about ages of stroke non 
hemorrhagic patients, their range were 56-
70 (52,5 %) and 30 – 55 (47,5%). This is 
because one of stroke non hemorrhagic 
factor that can’t be control is age. It is about 
Tabel 1. Characteristics of stroke non hemorrhagic patients before and after implementation of 
clinical pathway 
 
Characteristics 
Before clinical pathway 
n (34) 
After clinical pathway 
n (34) 
 
P value 
Ages 63,97± 
8,744 
50 – 83 
63,03± 
11,642 
38 – 87 
P= 0,672* 
Gender : 
a. Male 
 
b. Female 
 
22 
(65 %) 
12 
(35 %) 
 
22 (68 %) 
 
11 (32 %) 
 
 
P= 0,881** 
 
P= 0,835** 
Complication of disease : 
a. Yes 
 
b. No 
 
17 
(50 %) 
17 
(50 %) 
 
27 
(79 %) 
7 
(21 %) 
 
P= 0,423** 
 
P= 0,353** 
* : Mann Whitney U Test 
** : Chi Square Test 
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degeneration process attack old. The vein 
will lose flexibility because of 
atherosclerosis.3 
Adults (> 55) have twice possibility from  
suffering of stroke non hemorrhagic.4 
2. Data distribution of gender 
The results showed that 65 % from 34 
patients before clinical pathway and 68 % 
from 34 patients after clinical pathway were 
male. The result of Chi Square Test explained 
that p value > 0,05 it  concluded that there 
were no significant difference about gender 
before and after clinical pathway. 64 % 
stroke non hemorrhagic patients were male. 
It is because males were more often smoking 
than female.5 
3. Data distribution of Complication of disease 
The results showed that 50 % or 17 
patients had complication disease during 
care before clinical pathway and 21 % or 7 
patients had complication disease during 
care after clinical pathway. The most 
complication disease of stroke non 
hemorrhagic that written on medical record 
patients was Urinary Tract Infection. The 
results of Chi Square Test showed that  p 
value > 0,05 it concluded that there were no 
significant difference about both of groups. 
The same result was showed that about 9 % 
patients with complication disease before 
clinical pathway and 5,92 % patients with 
complication disease after clinical pathway. 
Statistics result showed that p value were 
0,480 > 0,05 it concluded that there were no 
significant difference about both of groups.6 
 
Based on statistic test, both of groups  
showed that data distribution weren’t normal. 
So statistic test used Mann Whitney U test. The 
average of stroke non hemorrhagic patients on 
Length Of Stay (LOS) before clinical pathway 
were 7,32±4,297 day and after clinical pathway 
were 5,32±1,512 day. The result of Mann 
Whitney U Test explained that p value < 0,05 it 
concluded that there were significant difference 
about two groups analyzed.  The same result 
shows that the everage of Length Of Stay after 
clinical pathway implementation were 7.3 ± 0.5 
day and before clinical pathway implementation  
were 10.9 ± 1.2 day. It concluded that there 
were significant diference because p < 0,05.7 
Other researches with some different result 
Table 2. The difference of stroke non hemorrhagic patients length of stay before and after clinical 
pathway. 
 Before clinical 
pathway (day) 
n = 34 
After clinical 
pathway (day) 
n = 34 
P 
values 
The average of Length Of Stay 
patients 
7,32 ± 4,297 5,32 ± 1,512 0,014* 
The average of Length Of Stay 
patients  with complication disease 
 
8,76 ± 5,506 
 
5,43  ± 0,976 
 
0,043* 
* =  Mann Whitney U Test 
 
Table 3.  The difference of stroke non hemorrhagic patients cost of treatment before and after clinical 
pathway 
 Before clinical pathway 
(Rp) 
n = 34 
After clinical pathway 
(Rp) 
n = 34 
P values 
The average of cost of 
treatment  
8.198.691 ± 
10.026.026 
2.613.000 – 61.017.000 
6.362.543 ± 3.249.981 
2.373.500  – 13.062.000 
0,447* 
The average of cost of 
treatment with complication 
disease 
11.222.382 
±13.552.217 
3.160.500 – 61.017.000 
8.157.738 ±4.054.705 
3.830.500 – 13.025.666 
0,824* 
* =  Mann Whitney U Test 
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showed that clinical pathway implementation 
weren’t given an impact to decrease the average 
of Length Of Stay (LOS) and cost of treatment.8  
Same result showed that clinical pathway of 
Congestive Hearth Failure hadn’t different on 
patients Length Of Stay and cost of treatment.9 
Patient’s Length Of Stay (LOS) with 
complication disease before and after clinical 
pathway were 8,76 ± 5,506 day and 5,43 ± 
0,976 day with p value based from Mann 
Whitney U Test < 0,05. It concluded that there 
were significant difference about two groups 
analyzed.  This result implied that clinical 
pathway were effective to decrease number of 
complication disease. The same result also 
showed about clinical pathway on Acute 
Myocardial Infarction that Patient’s Length Of 
Stay had significant decreased.10 But, others 
results also showed by some researcher who 
interested about clinical pathway management 
in hospital. That clinical pathway had no 
significant difference for stroke diagnosis. It was 
happened because of clinical pathway hadn’t 
implemented effectively.11 The same result also 
showed that after their research about clinical 
pathway on Pneumonia that had no significant 
difference about two of groups (before and after).  
The result also showed that clinical pathway 
couldn’t affort to decrease the number of 
patients mortality because of complication 
disease.12 Another research about clinical 
pathway showed that clinical pathway on renal 
transplant. The average of patient’s Length Of 
Stay with complication disease before clinical 
pathway explained that standar deviation value 
was 38,9 day and after clinical pathway was 18,9 
day.  P value > 0,002 there were no significant 
difference.13 
Based on statistics test, both of groups 
explained that data distribution weren’t normal. 
So statistics test used Mann Whitney U test. The 
average of patient’s cost of treatment without 
other factor correlation before clinical pathway 
were Rp. 8.198.691± Rp. 10.026.026 with 
minimum and maximum cost Rp. 2.613.000 – Rp. 
61.017.000. While after clinical pathway were 
Rp. 6.362.543 ± Rp. 3.249.981 with minimum 
and maximum cost were Rp.2.373.500 – Rp. 
13.062.000. P value > 0,05, it concluded that 
clinical pathway hadn’t significant difference. 
Although there were any decreased about cost of 
treatment after clinical pathway implementation 
but it didn’t meant statistically. The same results 
were showed that background on increased of 
CVA’s cost of treatment. His results explained 
that clinical pathway could efford to decrease  
cost of treatment amount 14,6 %. But it hadn’t 
significant difference.7 The same result also 
showed that even though  the result explain that 
there were decreased about cost of treatment 
but it hadn’t statistically significant difference.14 
The average of patient’s cost of treatment 
before clinical pathway were Rp. 11.222.382 ± 
Rp. 13.552.217 with minimum and maximum 
cost were Rp. 3.160.500 – Rp. 61.017.000 while 
after clinical pathway were Rp.8.157.738 ± 
Rp.4.054.705 with minimum and maximum cost 
were Rp.3.830.500 – Rp.13.025.666. P value 
showed that > 0,05 so it concluded that there 
were no significant difference about two groups. 
The same results were showed on clinical 
pathway of TURP at Aga Khan University 
Hospital. Those results explained that there were 
significant increased about completing 
documentation, consultation and education for 
patients family. But from those results there 
were no significant difference about cost of 
treatment before and after clinical pathway.15 
Another same results explained that clinical 
pathway of liver had significant decreased. But 
clinical pathway with complication disease 
correlation to outcomes hadn’t significant 
difference.16 
The development and implementation of a 
clinical pathway for patients with stroke during 
acute hospital phase can positively affect 
outcome in the form of reductions in length of 
stay, charges, and complications while 
improving and standardizing the quality of care.7 
The implementation of clinical pathway is 
most likely to succeed when the decision to 
developing is take on an organizational basis. 
Senior management commitment and a strong 
medical and nursing are essential. Pathway 
documentation is more likely to be used if it is 
simple, clear and user friendly. The process of 
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pathway development considers why tasks and 
interventions are performed, and by whom, 
since it promotes greater awareness of the role 
of each professional involved in the care cycle.17  
Success of clinical pathway implementation 
can be achieved by good organization of 
physician who serve medical care because 
clinical pathway are  structured multidisciplinary 
care plans which detail essential steps in the 
care of patients with a specific clinical problem. 
They have been proposed as a way of 
encouraging the translation of national guideline 
into local protocols and their subsequent 
application to clinical practice. They are also a 
means of improving systematic collection and 
abstraction of clinical data for audit and of 
promoting change in practice.1  
The main areas of concern for the patients of 
stroke are the treatment and outcomes and 
discover the ways for optimum management of a 
stroke patient. There is a certainty that if the 
patients stroke receive organized care, they will 
surely have better outcomes and prognosis. In a 
hospital setting, the well-trained staff and 
multidisciplinary approach to treatment and care 
characterize the stroke unit. The core disciplines 
for such multidisciplinary teams are: medical 
treatment, nursing, physiotherapy, occupational 
therapy, speech, language therapy and social 
work. The Clinical Pathways ensure a goal-
defined, making certain a well-defined efficient 
diagnosis, organized and time-specified plan of 
treatment of the patients with stroke, which can 
as certain evidence based practice and an 
improvement in the quality of outcomes at a 
lower cost.18  
They are designed to explicitly define what 
kind of continuity of care the patients should 
receive, at what time they should receive this 
care and what are the roles of the various 
multidisciplinary teams in the patient care. It has 
been seen, without much of much evidence to 
support this, which integrated care pathways are 
increasingly being implemented into the care of 
the patients with acute stroke and rehabilitation 
of the stroke patients. They have been shown to 
improve the patient outcomes, the quality of the 
care, decrease in the interventions ordered for 
the patients and decrease in the costs and also 
decrease in the length of the stay. They should 
not be seen as a ‘cookbook’ for healthcare – with 
prescriptive, step-by-step instructions – but 
rather as a set of appropriate, evidence-based 
activities and interventions for a specific user 
group. Care pathways are instruments that can 
reduce improper access to hospital emergency 
services, inappropriate admissions and 
unplanned discharges. So, to a great extent, they 
can help avoid 
unmotivated and undesirable interruptions 
of care, which can damage people in need and be 
a waste of resources. Wasted resources are 
particularly common in situations where 
different professionals intervene without 
consulting each other, creating unnecessary and 
costly overlaps and confusion.18 
 
D.  Conclusion 
The average of stroke non hemorrhagic 
patients on Length Of Stay (LOS) both groups 
without other variable correlation and 
complication disease correlation before and after 
clinical pathway implementation (P < 0,05) it 
concluded that there were significant difference 
that meant clinical pathway implementation 
effective to decrease number of complication 
disease. However, the average of stroke non 
hemorrhagic patients on cost of treatment both 
groups without other variable correlation and 
complication disease correlation before and after 
clinical pathway implementation ( P > 0,05) 
there were no significant difference that meant 
decreased Patient’s Length Of Stay (LOS) wasn’t 
given impact to decrease patient’s cost of 
treatment.  
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